diethylcarbamazine (Rx)

Brand and Other Names:Hetrazan
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

Not commercially available in the U.S.

Diethylcarbamazine is available from the CDC Drug Service for patients via an IND protocol for treatment of certain filarial diseases, including lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori; tropical pulmonary eosinophilia; and loiasis

It is also available for prophylactic use in persons determined to be at increased risk for Loa loa infection

To obtain, contact the CDC at 404-718-4745 or email parasites @cdc.gov

tablet

  • 100mg

Filarial Diseases

IND protocol from CDC available for treatment of certain filarial diseases, including lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori

Day 1: 50 mg PO PC

Day 2: 50 mg PO TID

Day 3: 100 mg PO TID

Day 4-14: 6 mg/kg/day PO divided TID

Loa Loa

Day 1: 50 mg PO PC

Day 2: 50 mg PO TID

Day 3: 100 mg PO TID

Day 4-21: 9 mg/kg/day PO divided TID

M. Streptocerca

6 mg/kg PO qDay x14 days 

Tropical Pulmonary Eosinophilia

IND protocol from CDC available for treatment of tropical pulmonary eosinophilia

Pulmonary eosinophilia, tropical: 6 mg/kg/day divided TID x14 days 

Larva Migrans, Visceral

6 mg/kg/day PO divided TID x7-10 days 

Dosage Forms & Strengths

Not commercially available in the U.S.

Diethylcarbamazine is available from the CDC Drug Service for patients via an IND protocol for treatment of certain filarial diseases, including lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori; tropical pulmonary eosinophilia; and loiasis

It is also available for prophylactic use in persons determined to be at increased risk for Loa loa infection

To obtain, contact the CDC at 404-718-4745 or email parasites @cdc.gov

tablet

  • 100mg

Filarial Diseases

IND protocol from CDC available for treatment of certain filarial diseases, including lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori

Day 1: 1 mg/kg PO PC

Day 2: 1 mg/kg PO TID

Day 3: 1-2 mg/kg PO TID

Day 4-14: 6 mg/kg/day PO divided TID

Loa Loa

Day 1: 1 mg/kg PO PC

Day 2: 1 mg/kg PO TID

Day 3: 1-2 mg/kg PO TID

Day 4-21: 9 mg/kg/day PO divided TID

Dosing Considerations

Pulmonary eosinophilia, tropical: See adult dosing

Larva migrans, visceral: See adult dosing

Next:

Adverse Effects

Frequency Not Defined

Encepholopathy (rare)

Fever

GI disturbances

Previous
Next:

Warnings

Contraindications

No studies reported

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: X

Lactation: not known if excreted in breast milk

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next:

Pharmacology

Mechanism of Action

Microfilaricidal and macrofilaricidal

Pharmacokinetics

Absorption: readily

Distribution: widely distributed throughout all body compartments, except adipose tissue

Half-life: 8 hr

Peak Plasma Time: 1-2 hr

Peak Plasma Concentration: (50 mg dose) 80-200 ng/mL

Metabolites: diethylcarbamazine N-oxide

Excretion: urine and feces

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.